Sera Prognostics, Inc. (NASDAQ:SERA) General Counsel Benjamin Jackson Sells 13,272 Shares

Sera Prognostics, Inc. (NASDAQ:SERA) General Counsel Benjamin Jackson sold 13,272 shares of the firm’s stock in a transaction on Friday, January 10th. The shares were sold at an average price of $7.42, for a total value of $98,478.24. Following the completion of the sale, the general counsel now directly owns 128,473 shares in the company, valued at approximately $953,269.66. This represents a 9.36 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink.

Benjamin Jackson also recently made the following trade(s):

• On Monday, January 13th, Benjamin Jackson sold 7,912 shares of Sera Prognostics stock. The stock was sold at an average price of $6.38, for a total value of $50,478.56.
• On Monday, November 11th, Benjamin Jackson sold 4,727 shares of Sera Prognostics stock. The shares were sold at an average price of $7.32, for a total value of $34,601.64.

Sera Prognostics Trading Up 3.8 %

SERA stock opened at $6.61 on Thursday. The firm has a 50-day moving average price of $7.44 and a 200-day moving average price of $7.31. Sera Prognostics, Inc. has a 12 month low of $4.98 and a 12 month high of $12.35. The stock has a market capitalization of $223.23 million, a P/E ratio of -6.68 and a beta of 0.86.

Sera Prognostics (NASDAQ:SERA) last released its quarterly earnings data on Wednesday, November 6th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.02). The company had revenue of $0.03 million for the quarter, compared to analyst estimates of $0.09 million. During the same period last year, the company posted ($0.23) EPS. As a group, equities analysts predict that Sera Prognostics, Inc. will post -0.96 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the company. Quest Partners LLC grew its position in Sera Prognostics by 533.5% during the 3rd quarter. Quest Partners LLC now owns 6,430 shares of the company’s stock worth $50,000 after acquiring an additional 5,415 shares during the last quarter. The Manufacturers Life Insurance Company bought a new stake in shares of Sera Prognostics during the second quarter worth about $68,000. SG Americas Securities LLC bought a new position in Sera Prognostics in the 3rd quarter valued at approximately $78,000. Prime Capital Investment Advisors LLC bought a new position in Sera Prognostics in the 3rd quarter valued at approximately $104,000. Finally, Jane Street Group LLC boosted its position in Sera Prognostics by 24.8% during the 3rd quarter. Jane Street Group LLC now owns 14,225 shares of the company’s stock worth $111,000 after buying an additional 2,826 shares during the period. 54.64% of the stock is currently owned by institutional investors.

About Sera Prognostics

Sera Prognostics, Inc, a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies.